Visit Patient Landing Page

You are now leaving our website.

If you click “Continue” below, you will leave the current site and be taken to a site maintained by a third party that is solely responsible for its content. Amgen provides this link as a service to website visitors. Amgen is not responsible for the privacy policy of any third-party websites. We encourage you to read the privacy policy of every website you visit.

Continue Cancel
hcp_home_banner
hcp_mobile_banner
Within 1 Year
of an MI
Nearly
PATIENTS have
another CV event 1*
*CV event = composite of ischemic stroke, recurrent myocardial
infarction, or all-cause death.
plaue-buildup

High LDL-C is a major cause of CV events and one of the most modifiable risk factors2-4

You may be actively managing patients with ASCVD who have several risk factors for a CV event, but reducing LDL-C is critical. It’s the main driver of ASCVD, and it can be effectively managed with diet, exercise, and treatment.
See how LDL-C is a critical risk factor
ascvd-desktop
ascvd-mobile

Lower LDL-C is better for patients with ASCVD5-7

Treatment guidelines for patients with ASCVD have evolved over time, recommending more intensive LDL-C lowering to reduce the risk of CV events. Studies have suggested no meaningful association between low levels of LDL-C and safety outcomes. Your patients with ASCVD at very high risk are Living in the Red if their LDL-C is not < 55 mg/dL.
Review the current LDL-C recommendations

More than 90% of patients who've had a prior myocardial infarction are at very high risk and may not know it9

Identifying each patient’s risk status helps you tailor your treatment
plan to achieve their recommended level of LDL-C.10

2018 AHA/ACC/Multi-society guideline definition of

very high-risk ASCVD10

Layer_1
1 Major EVENT + multiple
HIGH-RISK CONDITIONS
(such as: age ≥ 65 years, diabetes, hypertension)
Frame 133
Multiple major
events
(including: prior history of myocardial infarction, prior stroke, symptomatic PAD, acute coronary syndrome within 12 months)
Identify your very high-risk patients

Despite lipid-lowering treatment, most patients with ASCVD at very high risk do not have an LDL-C level of < 55 mg/dL11

Low percent of patients receiving statins ± ezetimibe achieve
LDL-C < 55 mg/dL

circle-1

20%with low to
moderate
intensity statin

circle-2

26%with high
intensity statin

Based on the 2022 ACC ECDP recommendation for patients with ASCVD at very high risk8

manage-ldl-c

* After evaluating the optimization of lifestyle, adherence to guideline-recommended statin therapy, risk factor control, statin associated side effects, and escalating to high intensity statin if not already taken.

graph-50-sm
scan_mobile
Identify your patients with ASCVD who are very high risk
See the Definition

AHA/ACC = American Heart Association/American College of Cardiology; ASCVD = atherosclerotic cardiovascular disease; ECDP = Expert Consensus Decision Pathway; MI = myocardial infarction; PAD = peripheral artery disease.

  • References

    1. Spertus J, Bhandary D, Fonseca E, et al. Contemporary incidence of recurrent cardiovascular events 1 to 3 years after myocardial infarction: longitudinal US analysis from NCDR registries linked with all-payer claims database. J Am Coll Cardiol. 2018;71:24.
    2. Ference BA, Ginsberg HN, Graham I, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J. 2017;38:2459-2472.
    3. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med. 2005;352:1685-1695.
    4. MedlinePlus. https://medlineplus.gov/cholesterol.html. Accessed July 25, 2024.
    5. Wilkinson MJ, Lepor NE, Michos ED. Evolving management of low-density lipoprotein cholesterol: a personalized approach to preventing atherosclerotic cardiovascular disease across the risk continuum. J Am Heart Assoc. 2023;12:1-22.
    6. Sabouret P, Angoulvant D, Cannon CP, Banach M. Low levels of low-density lipoprotein cholesterol, intracerebral haemorrhage, and other safety issues: is there still a matter of debate? Eur Heart J Open. 2022;2:1-5.
    7. Masana L, Girona J, Ibarretxe D, et al. Clinical and pathophysiological evidence supporting the safety of extremely low LDL levels-the zero-LDL hypothesis. J Clin Lipidol. 2018;12:292-299.
    8. Lloyd-Jones DM, Morris PB, Ballantyne CM, et al. 2022 ACC Expert Consensus Decision Pathway on the role of nonstatin therapies for LDL-cholesterol lowering in the management of atherosclerotic cardiovascular disease risk: a report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. 2022;80:1366-1418.
    9. Muntner P, Orroth KK, Mues KE, et al. Evaluating a simple approach to identify adults meeting the 2018 AHA/ACC cholesterol guideline definition of very high risk for atherosclerotic cardiovascular disease. Cardiovasc Drugs Ther. 2022;36:475-481.
    10. Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2019;73:3168-3209.
    11. Data on file, Amgen; 2023.